摘要
目的:探讨普瑞巴林联合血液灌流治疗维持性血液透析患者难治性皮肤瘙痒的临床疗效。方法:选取维持性血液透析难治性皮肤瘙痒患者80例,随机分为对照组及治疗组,对照组予血液透析加血液灌流治疗,治疗组在对照组基础上加用普瑞巴林口服,观察治疗前后临床指标,及视觉模拟量表(VAS)评分、改良Duo瘙痒评分。结果:治疗后组间比较,治疗组患者VAS评分和改良Duo瘙痒评分较对照组降低(P<0.05)。两组治疗后不良反应发生率无明显差异(P>0.05)。结论:普瑞巴林联合血液灌流治疗维持性血液透析患者皮肤瘙痒能显著改善症状,不良反应发生率低。
Objective:To explore the clinical effect of pregabalin combined with hemoperfusion on refractory pruritus among patients undergoing maintenance hemodialysis(MHD).Methods:Eighty MHD patients suffering from pruritus were enrolled in this study and randomized into a control group and a treatment group with 40 cases each.The control group underwent hemoperfusion,while the treatment group was given pregabalin combined with hemoperfusion.Clinical indicators,visual analogue scale(VAS)scores and the improved Duo pruritus scores were measured before and after the treatment.Results:VAS scores and the improved Duo pruritus scores were lower in the treatment group than the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups after treatment(P>0.05).Conclusion:Pregabalin combined with hemoperfusion can significantly improve the symptoms of the MHD patients with pruritus and the incidence of adverse reactions is low.
作者
沈娴文
朱俊
张瑞林
韩静
SHEN Xianwen;ZHU Jun;ZHANG Ruilin;HAN Jing(Department of Nephrology,the Fourth People’s Hospital of Taizhou,Taizhou 225300,China)
出处
《上海医药》
CAS
2023年第15期23-25,65,共4页
Shanghai Medical & Pharmaceutical Journal
